Bladder Adjuvant Radiotherapy
ForPost-cystectomy MIBC, pT3-4 / pN+ / margin+ / ≤10 nodes dissected
87.1% v 76.0%
HR 0.43 (95% CI, 0.20 to 0.96), P = .04
TL;DR2yr LRFS 87.1% vs 76.0% with adjuvant pelvic IMRT after RC, HR 0.43 (0.20-0.96), P=.04; DFS/BCSS/OS not significant.
The RT read is the target volume and the technique: stoma-sparing IG-IMRT, 50.4Gy/28fx to cystectomy bed plus pelvic nodes, with no additional severe toxicity reported. That combination is deliverable in a standard department today, so this moves the offer-vs-observe decision for a pT3-4 or pN+ postcystectomy patient rather than leaving adjuvant pelvic RT as a historical toxicity concern.
In a postcystectomy MIBC patient with pT3-4, pN+, positive margin, or ≤10 nodes dissected who has completed perioperative chemotherapy, this supports discussing adjuvant pelvic RT for locoregional control; it does not address patients who received adjuvant immunotherapy.
The transferable detail is the technique: stoma-sparing IG-IMRT, 50.4Gy/28fx to cystectomy bed plus pelvic nodes, with no additional severe toxicity reported. Elective nodal coverage was standard in the treated volume. This moves the offer-versus-observe decision for pT3-4 or pN+ postcystectomy patients.
Over 90% of patients received perioperative chemotherapy (71% neoadjuvant), so the RT benefit sits on top of a modern systemic backbone rather than substituting for it. No patient received immunotherapy, so how adjuvant RT interacts with adjuvant checkpoint blockade in this same high-risk group is untested here.
Surgical adequacy is embedded in eligibility: ≤10 nodes dissected and positive margin were qualifying high-risk features alongside T3-4 and N1-3. That reframes a limited lymphadenectomy or a close margin as a trigger for adjuvant RT referral rather than observation.
10 details
Multicenter phase III RCT, 1:1 adjuvant RT versus observation after radical cystectomy. 153 patients randomly assigned June 2016 to May 2024 (Obs 76, RT 77), stratified by nodal involvement and chemotherapy timing. Median follow-up 47 months.
Nonmetastatic urothelial MIBC, high risk after RC by any one of T3-4, N1-3, positive margin, or ≤10 nodes dissected. Baseline load was heavy: 62% pT3-T4 and 41% pN+.
Over 90% received systemic chemotherapy (71% neoadjuvant, 20% adjuvant). None received immunotherapy in either arm.
Stoma-sparing IG-IMRT, 50.4Gy in 28 fractions, prescribed to the cystectomy bed and pelvic nodes. Elective nodal coverage was part of the treated volume, not an optional add-on.
Primary: 2-year locoregional recurrence-free survival. Secondary: disease-free survival, bladder cancer-specific survival, overall survival.
The primary endpoint was met; secondary endpoints all favored RT numerically without reaching significance. See the endpoint table for arm-level rates and hazard ratios.
| Endpoint | RT | Obs | HR (95% CI) |
|---|---|---|---|
| LRFS (1°) | 87.1% | 76.0% | 0.43 (0.20-0.96), P=.04 |
| DFS | 71.6% | 58.7% | 0.62 (0.36-1.05) |
| BCSS | 79.6% | 65.0% | 0.59 (0.33-1.10) |
| OS | 70.4% | 57.4% | 0.78 (0.49-1.26) |
The authors report no additional severe toxicity with adjuvant pelvic IMRT. Grade-level AE breakdown is not reported in the source abstract.
The primary endpoint is a 2-year locoregional readout under a 47-month median follow-up, so the headline reports early control rather than durability. Accrual spanned eight years, during which adjuvant immunotherapy entered practice in this exact population, and the control arm reflects none of it.
Adjuvant pelvic RT after cystectomy has been an open question since the older Egyptian NCI randomized experience, which used larger fields and conventional technique. This is the modern IMRT-era answer, and it lands positive on local control only, not survival.
A HR of 0.43 on locoregional control with an upper CI bound of 0.96 is a real but fragile signal in 153 patients. The consistent numeric direction across DFS (HR 0.62), BCSS (HR 0.59), and OS (HR 0.78) is reassuring but underpowered, and none of it settles whether locoregional control converts to survival.
CONSORT flow
Randomised, prespecified 2yr LRFS primary endpoint met in a setting where adjuvant RT is not standard. Small N and borderline CI limit confidence, not internal validity.
- Does locoregional benefit persist alongside adjuvant immunotherapy
- Does 2yr LRFS gain translate to survival with longer follow-up
- Which high-risk feature drives the benefit: pN+, margin, or nodal yield
📚 Sources · 📄 1 paper
Abstract
The longer read
The value of this trial is that it answers a question the field mostly stopped asking. Adjuvant radiotherapy after radical cystectomy fell out of favor less because it failed than because the older randomized experience used large fields and conventional technique, and the bowel toxicity that followed made the tradeoff untenable. Once perioperative chemotherapy became standard, the locoregional failure problem did not disappear, it simply became something surgeons and medical oncologists absorbed rather than treated. What is new here is not the hypothesis but the delivery: stoma-sparing image-guided IMRT at 50.4Gy in 28 fractions to the cystectomy bed and pelvic nodes, with the authors reporting no additional severe toxicity. That technical detail is what should move a reader's confidence, because it is the variable that changed between the historical negative-in-practice experience and this result.
On the efficacy side the read should be more restrained than the headline suggests. A hazard ratio of 0.43 for two-year locoregional recurrence-free survival is a large effect, but the interval runs to 0.96 and the P value is .04, which in a 153-patient trial accruing over eight years means the result rests on a small absolute number of events. The 87.1% versus 76.0% difference is the honest way to read the magnitude, and it is an eleven-point separation at two years in a population where 62% were pT3-T4 and 41% node positive. Whether that separation widens or converges past two years is genuinely unknown, and the 47-month median follow-up means the trial had the data to look further but reported the endpoint it registered.
The secondary endpoints deserve a careful reading rather than dismissal. Disease-free survival, cancer-specific survival, and overall survival all point the same direction, with hazard ratios of 0.62, 0.59, and 0.78 respectively, and none crosses into significance. Two readings are available and the source does not adjudicate between them. Either the trial is underpowered for survival and these are early glimpses of a real downstream effect, or locoregional control in this disease is largely uncoupled from survival because distant failure dominates the natural history. The attenuation from 0.59 on cancer-specific survival to 0.78 on overall survival is at least consistent with competing mortality in a heavily pretreated older cohort, and a reader should not treat the numeric consistency as confirmation.
The single most important limitation for anyone applying this in 2026 is the one the trial could not have avoided. None of these patients received immunotherapy, and adjuvant checkpoint blockade is now offered in exactly this high-risk postcystectomy setting. The control arm therefore represents a standard of care that has moved, and it is unresolved whether the locoregional benefit persists on top of an adjuvant systemic agent, whether the toxicity profile of concurrent or sequential delivery is acceptable, or whether the two interventions are addressing the same fraction of failures. For a radiation oncologist the practical position is that this trial legitimizes offering adjuvant pelvic RT to a well-selected pT3-4 or node-positive patient after cystectomy and chemotherapy, with the discussion framed honestly around local control, and with the immunotherapy question stated as open rather than answered.